WP
CBIO

Woodline Partners’s Crescent Biopharma CBIO Stock Holding History

Woodline Partners’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7M Buy
94,488
+20,488
+28% +$400K 0.01% 854
2026
Q1 		$1.36M Hold
74,000
– – 0.01% 842
2025
Q4 		$878K Buy
+74,000
New +$943K ﹤0.01% 849

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Woodline Partners's CBIO Position: Q2 2026 in Review

Woodline Partners increased its Crescent Biopharma (CBIO) stake by 28% in Q2 2026, buying an estimated $400K and bringing the position to 94,488 shares worth $1.7M. The position accounts for 0.01% of the portfolio, ranked #854.

Woodline Partners first reported a position in CBIO in Q4 2025 and has held it in 3 quarters since. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Woodline Partners held 94,488 shares of Crescent Biopharma worth $1.7M as of Q2 2026.
  • Woodline Partners bought 20,488 Crescent Biopharma shares in Q2 2026, an estimated $400K.
  • Crescent Biopharma made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #854 holding.
  • Woodline Partners first reported a position in Crescent Biopharma in Q4 2025 and has held it in 3 quarters since.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.